EATONTOWN, N.J., July 10, 2013 (GLOBE NEWSWIRE) — American CryoStem Corporation (CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that its protocols for the processing of Stromal Vascular Fraction (SVF) and culturing of mesenchymal stem cells from autologous adipose tissue have been approved by the Institutional Review Board (IRB) of the International Cell Surgical Society (ICSS).
The two stem cell processing protocols are titled: 1) Autologous Adipose Tissue-Derived Stromal Vascular Fraction (SVF) Containing Adult Stem Cells with Isolation of SVF and 2) Culturing of Adipose-Derived Stem Cells (ADSCs) For Use in Institutional Review Board Studies. These protocols provide appropriate testing methods necessary to move the clinical investigative process towards uniform treatments, and the collection of cGMP processing and outcome data required by prevailing FDA regulations and guidance for approval of regenerative cellular therapies, including potency (cell count), contamination testing and cell viability.
The Company will make available its processing services utilizing the IRB approved protocols to physicians and clinical researchers for inclusion in their studies. By adopting these protocols and the laboratory services of American CryoStem, researchers can focus their resources on application development rather than creating, validating, and managing a clinical laboratory for processing tissue and cellular samples. These protocols do not involve actual human clinical trials, but affords the IRB the opportunity to endorse standardized and validated processing methodologies for the isolation of SVF and for tissue culture expansion of ADSCs obtained from SVF.
The ICSS IRB thoroughly evaluated every step of American CryoStem’s processing protocols, which serve to isolate the SVF or ADSCs from a patient’s adipose tissue. The objective of the IRB is to assess these protocols to ensure the highest patient safety possible and to minimize the risks for those participating in innovative research and investigational studies.
“The purpose of obtaining IRB approval of our processing protocols is to make it easier for physicians to study the safety of SVF and ADSCs using a standardized processing methodology that characterizes, as well as tests the sample for sterility and viability,” stated John S. Arnone, Chairman and CEO of American CryoStem Corporation.
The ICSS IRB is comprised of medical and scientific experts as well as informed community members. The IRB is registered with the Office for Human Research Protections (OHRP), a part of the U.S. Department of Health and Human Services. The IRB, managed by International Cell Surgical Society, is a California based physician organization dedicated to education, advancing research and advocating for cell-based regenerative medicine.
“In view of the extraordinarily rapid and extensive use of Adipose-Derived Stem Cells clinically, it is imperative that standards for processing and identification of these cells be established along with cGMP data collection to assure that the cells used in the patients’ treatments are in fact SVF or ADSCs,” stated David Audley, Chairman of International Cell Surgical Society.
For more information please contact firstname.lastname@example.org or call us directly at 732-747-1007.
About American CryoStem Corporation
A pioneer in the fields of Regenerative and Personalized Medicine, American CryoStem is a developer, marketer and global licensor of patented adipose tissue-based cellular technologies and related proprietary services with a focus on clinical processing, commercial bio-banking and application development for adipose (fat) tissue and autologous adipose-derived regenerative cells (ADRCs). The Company maintains a strategic portfolio of intellectual property and patent applications that form its Adipose Tissue Processing Platform, which supports and promotes a growing pipeline of biologic products and processes, clinical services and international licensing opportunities. Through its ACS Laboratories division, the Company operates an FDA registered, cGMP compliant human tissue processing, cryo-storage, cell culture and differentiation media development facility in Mount Laurel, New Jersey.
For more information, please visit www.americancryostem.com and www.acslaboratories.com.
This press release may contain forward-looking statements, including information about management’s view of American CryoStem Corporation’s (“the Company”) future expectations, plans and prospects. In particular, when used in the preceding discussion, the words “believes,” “expects,” “intends,” “plans,” “anticipates,” or “may,” and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this press release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by American CryoStem Corporation.